Gastric and Gastroesophageal Junction Adenocarcinoma Market Size and Trend Report including Epidemiology, Disease Management, Pipeline Analysis, Competitor Assessment, Unmet Needs, Clinical Trial Strategies and Forecast, 2019-2029
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
The Gastric and Gastroesophageal Junction Adenocarcinoma (G/GEJAC) market size across the 8MM was valued at $1.12 billion in 2019 and is forecast to grow at a CAGR of more than 15% during 2019-2029. Growth of the market will be driven by the recent expansions of Opdivo and Keytruda into the first-line metastatic setting, further expansions for multiple agents across the 8MM, and the launches of nine pipeline agents.
G/GEJAC Market Outlook, 2019 ( $ Billion)
To gain more information on the G/GEJAC market forecast, download a free report sample
G/GEJAC Market Drivers
The major drivers of growth in the G/GEJAC market across the 8MM over the forecast period include multiple label expansions for Bristol Myers Squibb’s (BMS’) Opdivo (nivolumab), increased adoption of expensive immunotherapies in the first-line and adjuvant settings, the approval and launch of premium-priced therapeutics in the 8MM, and the label expansions for Merck & Co.’s Keytruda (pembrolizumab) and AstraZeneca/Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan) that will result in greater adoption of more expensive combinatorial regimens.
G/GEJAC Market Segmentation by Class
The key classes in the G/GEJAC market are Generic Chemotherapies, Branded Chemotherapies, Targeted Therapies, and Immunotherapies. In 2021, Targeted Therapies were the leading class.
G/GEJAC Market Analysis, by Class, 2021 (%)
For more G/GEJAC class insights, download a free report sample
G/GEJAC Market - Competitive Landscape
Some of the leading players in the G/GEJAC market are Bristol Myers Squibb, Merck & Co, AstraZeneca, Daiichi Sankyo, F. Hoffmann-La Roche, Eli Lilly, BeiGene, Astellas, Zymeworks, and Seagen.
G/GEJAC Market Report Overview
Market Size (2019) | $1.12 billion |
CAGR (2019 – 2029) | >15% |
Forecast period | 2020-2029 |
Key Classes | Generic Chemotherapies, Branded Chemotherapies, Targeted Therapies, and Immunotherapies |
Leading Players | Bristol Myers Squibb, Merck & Co, AstraZeneca, Daiichi Sankyo, F. Hoffmann-La Roche, Eli Lilly, BeiGene, Astellas, Zymeworks, and Seagen |
G/GEJAC Market Classes Outlook (Value, $ Billion, 2019-2029)
- Generic Chemotherapies
- Branded Chemotherapies
- Targeted Therapies
- Immunotherapies
Scope
This report provides
- Overview of G/GEJAC including epidemiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.
- Topline G/GEJAC market revenue, annual cost of therapy, and major pipeline product sales in the forecast period.
- Key topics including current treatment and pipeline therapies, unmet needs and opportunities, and the drivers and barriers affecting G/GEJAC therapeutics sales in the 8MM.
- Comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of late-stage pipeline drugs (Phase II-III).
- Analysis of the current and future market competition in the global G/GEJAC therapeutics market. Insightful review of the key industry drivers and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
Reasons to Buy
The report will enable you to:
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global G/GEJAC therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global G/GEJAC market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counterstrategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.
Merck & Co
AstraZeneca
Daiichi Sankyo
F. Hoffmann-La Roche
Eli Lilly
BeiGene
Astellas
Zymeworks
Seagen
LintonPharm
ALX Oncology
Amgen
Zai Lab
Merck Sharp & Dohme Corp
ArQule Inc
RemeGen Co Ltd
Novartis Pharma AG
EQRx Inc
CM Life Sciences III Inc
Gilead Sciences Inc
Pionyr Immunotherapeutics Inc
CStone Pharmaceuticals Co Ltd
ABPro Bio Co Ltd
Abpro Corp
Flame Biosciences Inc
Novarock Biotherapeutics Limited
Sagard Holdings ULC
AnaptysBio Inc
Healthcare Royalty Partners LP
ADC Therapeutics SA
Table of Contents
Table
Figures
Frequently asked questions
-
What was the G/GEJAC market size in 2021?
The G/GEJAC market size was valued at $1.12 billion in 2019.
-
What is the G/GEJAC market growth rate?
The G/GEJAC market is expected to achieve a CAGR of more than 15% during 2019-2029.
-
What are the key classes in the G/GEJAC market?
The key classes in the G/GEJAC market are Generic Chemotherapies, Branded Chemotherapies, Targeted Therapies, and Immunotherapies.
-
Who are the leading players in the G/GEJAC market?
Some of the leading players in the G/GEJAC market are Bristol Myers Squibb, Merck & Co, AstraZeneca, Daiichi Sankyo, F. Hoffmann-La Roche, Eli Lilly, BeiGene, Astellas, Zymeworks, and Seagen.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.